Atea Pharmaceuticals Inc (AVIR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.33 (+1.33%), Market cap $0.43B, 52-week low–high $2.55 ~ $6.15.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD Internatio
Financial statements, price targets, institutional (13F) holdings and related news for Atea Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Atea Pharmaceuticals Inc trades at $5.33 (+1.33%). Real-time quotes and charts are available on BlackAll Trade.
Atea Pharmaceuticals Inc has a market cap of about $0.43B.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product